Lectures and seminars OnkPat Friday Seminar: Chemoresistance, immunomodulation, tumour suppression: interconnected and context-dependent roles of SAMHD1
Welcome to the OnkPat Friday Seminar with Nikolas Herold, Department of Women's and Children's Health.
Host: Sean Rudd, Department of Oncology-Pathology.
Short Bio
Nikolas is a paediatric oncologist at Astrid Lindgren Children's Hospital, early-phase clinical trial at the Stockholm centre for Innovative Treatment for Children and Adolescents with Cancer (ITCC), and leader of the research group "Translational Research in Childhood Cancer" at Karolinska Institutet. His main interest is understanding and targeting resistance to chemotherapy and immunotherapy with the goal of implementing rational clinical trials. He is a proponent of the paradigm that both fun at work and scientific progress are strongly enhanced through collaboration.
Related references
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T
Nat Med 2017 Feb;23(2):256-263
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, Hed Myrberg I, Bunten SS, Axelsson H, Zhang SM, Rasti A, Mäkelä P, Coggins SA, Tao S, Suman S, Branca RM, Mermelekas G, Wiita E, Lee S, Walfridsson J, Schinazi RF, Kim B, Lehtiö J, Rassidakis GZ, Pokrovskaja Tamm K, Warpman-Berglund U, Heyman M, Grandér D, Lehmann S, Lundbäck T, Qian H, Henter JI, Schaller T, Helleday T, Herold N
EMBO Mol Med 2020 Mar;12(3):e10419
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH, Lilienthal I, Lord M, Merrien M, Wasik AM, Sureda-Gómez M, Amador V, Johansson HJ, Lehtiö J, Garcia-Torre B, Martin-Subero JI, Tsesmetzis N, Tao S, Schinazi RF, Kim B, Sorteberg AL, Wickström M, Sheppard D, Rassidakis GZ, Taylor IA, Christensson B, Campo E, Herold N, Sander B
Blood 2024 May;143(19):1953-1964